Malaria treatment and follow up
infection
MALARIA, INFECTION, RECURRENCE
Participants diagnosed with uncomplicated In cases of recurrent malaria infection occurring on or after day 14, dried blood spots collected on filter paper from enrolment day and the day of recurrence of infection underwent extraction to distinguish new from recrudescent infection by genotyping merozoite surface protein-1 (MSP-1), MSP-2 and the glutamate-rich protein (GLURP) according to the publicly available protocol [Participants who consented to participate in a sub-study of lumefantrine drug concentration measurements were selected to submit blood specimens for day 7 drug levels. Participants were only enrolled 1 time. These participants were given 250 ml of milk to drink with each dose to ensure optimal and consistent lumefantrine absorption [Plasma was shipped to the Parikh laboratory at the Yale School of Public Health (New Haven, CT) on dry ice, and immediately transferred to NorthEast BioLab (Hamden, CT) for drug level analysis of lumefantrine and desbutyl-lumefantrine using liquid chromatography-tandem mass spectrometry on an API 5000 triple-quadruple mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, CA). The calibration range was 10.9–3785 ng/mL for lumefantrine, and 1.9–1130 ng/mL for desbutyl-lumefantrine with the lower limit of quantification (LLOQ) at 10.0 and 1.9 ng/mL for lumefantrine and desbutyl-lumefantrine, respectively. The coefficient of variation was 1.4% and 5.6% for lumefantrine and desbutyl-lumefantrine, respectively.